Drug Profile
SPI 183
Alternative Names: SPI183Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Selten Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in USA
- 23 Mar 2015 Phase-I clinical trials in Pulmonary arterial hypertension in USA (unspecified route)